X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs GLENMARK PHARMA - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS GLENMARK PHARMA NOVARTIS/
GLENMARK PHARMA
 
P/E (TTM) x 424.9 12.7 3,345.5% View Chart
P/BV x 30.0 2.3 1,317.8% View Chart
Dividend Yield % 1.5 0.5 330.2%  

Financials

 NOVARTIS   GLENMARK PHARMA
EQUITY SHARE DATA
    NOVARTIS
Mar-18
GLENMARK PHARMA
Mar-18
NOVARTIS/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs758930 81.5%   
Low Rs579517 111.9%   
Sales per share (Unadj.) Rs228.4322.6 70.8%  
Earnings per share (Unadj.) Rs31.728.5 111.4%  
Cash flow per share (Unadj.) Rs32.839.2 83.6%  
Dividends per share (Unadj.) Rs10.002.00 500.0%  
Dividend yield (eoy) %1.50.3 541.3%  
Book value per share (Unadj.) Rs297.1183.0 162.4%  
Shares outstanding (eoy) m24.69282.17 8.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.92.2 130.5%   
Avg P/E ratio x21.125.4 82.9%  
P/CF ratio (eoy) x20.418.5 110.5%  
Price / Book Value ratio x2.24.0 56.9%  
Dividend payout %31.57.0 448.8%   
Avg Mkt Cap Rs m16,505204,206 8.1%   
No. of employees `0000.713.7 4.9%   
Total wages/salary Rs m1,44518,718 7.7%   
Avg. sales/employee Rs Th8,441.36,636.8 127.2%   
Avg. wages/employee Rs Th2,163.61,364.7 158.5%   
Avg. net profit/employee Rs Th1,173.1586.1 200.2%   
INCOME DATA
Net Sales Rs m5,63991,031 6.2%  
Other income Rs m1,718914 188.0%   
Total revenues Rs m7,35791,945 8.0%   
Gross profit Rs m-6316,154 -0.4%  
Depreciation Rs m253,019 0.8%   
Interest Rs m552,856 1.9%   
Profit before tax Rs m1,57511,193 14.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7923,155 25.1%   
Profit after tax Rs m7848,039 9.7%  
Gross profit margin %-1.117.7 -6.2%  
Effective tax rate %50.328.2 178.3%   
Net profit margin %13.98.8 157.4%  
BALANCE SHEET DATA
Current assets Rs m9,52269,887 13.6%   
Current liabilities Rs m3,29632,879 10.0%   
Net working cap to sales %110.440.7 271.6%  
Current ratio x2.92.1 135.9%  
Inventory Days Days3781 45.0%  
Debtors Days Days2893 30.4%  
Net fixed assets Rs m4628,892 0.2%   
Share capital Rs m123282 43.7%   
"Free" reserves Rs m7,21351,353 14.0%   
Net worth Rs m7,33651,635 14.2%   
Long term debt Rs m041,418 0.0%   
Total assets Rs m11,105125,954 8.8%  
Interest coverage x29.54.9 599.3%   
Debt to equity ratio x00.8 0.0%  
Sales to assets ratio x0.50.7 70.3%   
Return on assets %7.68.6 87.3%  
Return on equity %10.715.6 68.6%  
Return on capital %22.215.1 147.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m6136,317 0.2%   
Fx outflow Rs m3,6309,720 37.3%   
Net fx Rs m-3,57026,598 -13.4%   
CASH FLOW
From Operations Rs m1,61016,481 9.8%  
From Investments Rs m687-10,133 -6.8%  
From Financial Activity Rs m-2,677-4,685 57.1%  
Net Cashflow Rs m-3801,770 -21.4%  

Share Holding

Indian Promoters % 0.0 48.3 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 6.9 29.0%  
FIIs % 1.6 34.4 4.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 10.5 204.8%  
Shareholders   41,647 56,727 73.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   ALEMBIC LTD  PANACEA BIOTECH  CADILA HEALTHCARE  TORRENT PHARMA  PLETHICO PHARMA  

Compare NOVARTIS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Yes Bank's Road Ahead(Podcast)

The stock markets witnessed selling pressure in the week gone by. Market participants remained cautious tracking tepid quarterly earnings amid weak cues.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 11.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, GLENMARK PHARMA has posted a net profit of Rs 1 bn (up 11.1% YoY). Sales on the other hand came in at Rs 26 bn (up 15.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY19); Net Profit Down 31.3% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Here's What to Do with Falling Small Cap Stocks(Profit Hunter)

Jul 10, 2019

There are some great buying opportunities in the market right now - and the small cap space is your best bet.

Budget an Icing on the Cake for This Smart Money Backed Affordable Housing Stock(The 5 Minute Wrapup)

Jul 10, 2019

Affordable housing is one of the most straightforward growth stories in India. This will help the real estate sector to come out of the slump.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Jul 19, 2019 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE NOVARTIS WITH

MARKET STATS